The Impact of Free Fatty Acid (FFA-) Suppression on Myocardial Lipids and Function in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
There is evidence that inhibition of FFA-release by acipimox is associated with a significant
decrease in myocardial lipid content (MYCL) as well as the ejection fraction (as a marker of
systolic left ventricular function) in healthy subjects, indicating, that the heart is
dependent on a constant supply of free fatty acids in order to guarantee normal cardiac
function, and it further indicates, that the heart is not able to cover its energy demand by
switching to glucose oxidation.
Since that phenomenon, better known as "metabolic inflexibility" has been mainly described in
patients with diabetes, we aim to investigate the impact of FFA-inhibition on MYCL and
cardiac function in patients with overt type 2 diabetes.